EICHORCondition: HIV · HIV Infections · Sponsor: ViiV Healthcare
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) who are of at least 50 years of age and above.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Phoenix, Arizona, United States | — |
| GSK Investigational Site | Bakersfield, California, United States | — |
| GSK Investigational Site | Palm Springs, California, United States | — |
| GSK Investigational Site | Washington D.C., District of Columbia, United States | — |
| GSK Investigational Site | Ft. Pierce, Florida, United States | — |
| GSK Investigational Site | Miami, Florida, United States | — |
| GSK Investigational Site | West Palm Beach, Florida, United States | — |
| GSK Investigational Site | Augusta, Georgia, United States | — |
| GSK Investigational Site | Decatur, Georgia, United States | — |
| GSK Investigational Site | Macon, Georgia, United States | — |
| GSK Investigational Site | Boston, Massachusetts, United States | — |
| GSK Investigational Site | Berkley, Michigan, United States | — |
+ 44 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05911360